The Effects of Combined Treatment with an HMG-CoA Reductase Inhibitor and PPARγ Agonist on the Activation of Rat Pancreatic Stellate Cells

키워드

참고문헌 (50)

1. Etemad B, "Chronic pancreatitis: diagnosis, classification, and new genetic developments", Gastroenterology, 120, pp.682~707 (2001)
2. Apte MV, "Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancre-atic fibrogenesis", Gut, 44, pp.534~541 (1999)
3. Haber PS, "Activation of pancreatic stellate cells in human and experimental pancreatic fibrosis", Am J Pathol, 155, pp.1087~1095 (1999)
4. Sparmann G, "Generation and characterization of immortalized rat pancreatic stellate cells", Am J Physiol Gastrointest Liver Physiol, 287, pp.G211~G219 (2004)
5. Masamune A, "Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis", Clin Gastroenterol Hepatol, 7(11 Suppl), pp.S48~S54 (2009)
6. Apte MV, "Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells", Pancreas, 29, pp.179~187 (2004)
7. Omary MB, "The pancreatic stellate cell: a star on the rise in pancreatic diseases", J Clin Invest, 117, pp.50~59 (2007)
8. Saotome T, "Morphological and immunocytochemical identification of periacinar fibroblast-like cells derived from human pancreatic acini", Pancreas, 14, pp.373~382 (1997)
9. Luttenberger T, "Platelet-derived growth factors stimulate proliferation and extracellular matrix synthesis of pancreatic stellate cells: implications in pathogenesis of pancreas fibrosis", Lab Invest, 80, pp.47~55 (2000)
10. Shek FW, "Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis", Am J Pathol, 160, pp.1787~1798 (2002)
11. Mews P, "Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis", Gut, 50, pp.535~541 (2002)
12. Hama K, "Angiotensin II promotes the proliferation of activated pancreatic stellate cells by Smad7 induction through a protein kinase C pathway", Biochem Biophys Res Commun, 340, pp.742~750 (2006)
13. Talukdar R, "Pancreatic stellate cells: new target in the treatment of chronic pancreatitis", J Gastroenterol Hepatol, 23, pp.34~41 (2008)
14. Ohnishi H, "Distinct roles of Smad2-, Smad3-, and ERK-dependent pathways in transforming growth factor-beta1 regulation of pancreatic stellate cellular functions", J Biol Chem, 279, pp.8873~8878 (2004)
15. Masamune A, "NADPH oxidase plays a crucial role in the activation of pancreatic stellate cells", Am J Physiol Gastrointest Liver Physiol, 294, pp.G99~G108 (2008)
16. Masamune A, "Protease-activated receptor-2-mediated proliferation and collagen production of rat pancreatic stellate cells", J Pharmacol Exp Ther, 312, pp.651~658 (2005)
17. Yamada T, "Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats", J Pharmacol Exp Ther, 313, pp.36~45 (2005)
18. Nagashio Y, "Angiotensin II type 1 receptor interaction is an important regulator for the development of pancreatic fibrosis in mice", Am J Physiol Gastrointest Liver Physiol, 287, pp.G170~G177 (2004)
19. Trebicka J, "Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells", J Hepatol, 53, pp.702~712 (2010)
20. Aprigliano I, "Atorvastatin induces apoptosis by a caspase-9-dependent pathway: an in vitro study on activated rat hepatic stellate cells", Liver Int, 28, pp.546~557 (2008)
21. Yanase M, "HMG-COA reductase inhibitor modulates collagen GEL-contraction by hepatic myofibroblastlike stellate cell line: involvement of geranylgeranylated proteins", Comp Hepatol, 3(Suppl 1), pp.S21~ (2004)
22. Hindler K, "The role of statins in cancer therapy", Oncologist, 11, pp.306~315 (2006)
23. Rombouts K, "Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells", J Hepatol, 38, pp.564~572 (2003)
24. Wu YM, "Pancreatic carcinoma cells stimulate proliferation and matrix synthesis of hepatic stellate cells", J Hepatol, 51, pp.307~314 (2009)
25. Kliewer SA, "A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation", Cell, 83, pp.813~819 (1995)
26. Forman BM, "15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma", Cell, 83, pp.803~812 (1995)
27. Chou FS, "Effects of thiazolidinediones on differentiation, proliferation, and apoptosis", Mol Cancer Res, 5, pp.523~530 (2007)
28. Michalik L, "Peroxisome-proliferatoractivated receptors and cancers: complex stories", Nat Rev Cancer, 4, pp.61~70 (2004)
29. Marra F, "Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells", Gastroenterology, 119, pp.466~478 (2000)
30. Miyahara T, "Peroxisome proliferatoractivated receptors and hepatic stellate cell activation", J Biol Chem, 275, pp.35715~35722 (2000)
31. Masamune A, "Ligands of peroxisome proliferator-activated receptor-gamma block activation of pancreatic stellate cells", J Biol Chem, 277, pp.141~147 (2002)
32. Jaster R, "Peroxisome proliferator-activated receptor gamma overexpression inhibits pro-fibrogenic activities of immortalised rat pancreatic stellate cells", J Cell Mol Med, 9, pp.670~682 (2005)
33. Ivashchenko CY, "PPAR-gamma knockout in pancreatic epithelial cells abolishes the inhibitory effect of rosiglitazone on caerulein-induced acute pancreatitis", Am J Physiol Gastrointest Liver Physiol, 293, pp.G319~G326 (2007)
34. Shimizu K, "Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgammaindependent mechanism", Pancreas, 29, pp.67~74 (2004)
35. Yao CJ, "Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone", Int J Cancer, 118, pp.773~779 (2006)
36. Mrówka P, "Ciglitazone, an agonist of peroxisome proliferator-activated receptor gamma, exerts potentiated cytostatic", cytotoxic effects against tumor cells when combined with lovastatin, 2008, pp.32, 249~255
37. Yano M, "Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1", 2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages, 2007, pp.100, 1442~1451
38. Grip O, "Atorvastatin activates PPARgamma and attenuates the inflammatory response in human monocytes", Inflamm Res, 51, pp.58~62 (2002)
39. Chang L, "Mammalian MAP kinase signalling cascades", Nature, 410, pp.37~40 (2001)
40. Jaster R, "Inhibition of pancreatic stellate cell activation by the hydroxymethylglutaryl coenzyme A reductase inhibitor lovastatin", Biochem Pharmacol, 65, pp.1295~1303 (2003)
41. 임선우, "Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy", American Journal of Physiology - Renal Fluid and Electrolyte Physiology, 286(1), pp.F46~F57, American Physiological Society
42. Wei JL, "Synergistic effects of pravastatin and pioglitazone in renal tubular epithelial cells induced by transforming growth factor-beta1", Cell Biol Int, 31, pp.451~458 (2007)
43. Bardou M, "Effect of statin therapy on colorectal cancer", Gut, 59, pp.1572~1585 (2010)
44. Hamilton RJ, "Review of recent evidence in support of a role for statins in the prevention of prostate cancer", Curr Opin Urol, 18, pp.333~339 (2008)
45. Hanefeld M, "Anti-inflammatory effects of pioglitazone and", or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study, 2007, pp.49, 290~297
46. Efuet ET, "Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome", Cancer Res, 66, pp.1040~1051 (2006)
47. Theocharis S, "Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators", Cancer Treat Rev, 30, pp.545~554 (2004)
48. Takeda I, "Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells", Cancer Sci, 98, pp.890~899 (2007)
49. Meloche S, "The ERK1", 2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition, 2007, pp.26, 3227~3239
50. Mebratu Y, "How ERK1", 2 activation controls cell proliferation and cell death: is subcellular localization the answer?, 2009, pp.8, 1168~1175

관련 논문AI추천